Patients in this category with TP53 mutations had a poor prognosis regardless of age (46,54,55,56). After treating patients with alkylating agents/ionizing radiation, patients often have increased blasts with associated multilineage dysplasia that cause similar mutation profiles like in AML-MRC. Here, TP53 is linked to acute myeloid leukemia.